Human papillomavirus (HPV) is a causal agent of cervical cancer, and persistent HPV16 or HPV18 infection carries a particularly high risk. The cobas HPV Test (cobas) provides individual HPV16/HPV18 genotyping with a simultaneous result for 12 other high-risk HPV (hrHPV) genotypes. Its analytical performance for hrHPV genotype detection was retrospectively evaluated against the digene Hybrid Capture 2 HPV DNA test (HC2), in three European centers, in 1360 cervical samples. Both HPV tests performed similarly, with no significant difference in the number of positive and negative samples identified by each test and good agreement between the tests was observed. Discordant samples were analyzed with the Linear Array HPV genotyping test. More low-risk HPV (lrHPV) genotypes were detected in HC2-positive/cobas-negative samples compared with HC2-negative/cobas-positive samples. Conversely, more hrHPV genotypes were detected in HC2-negative/cobas-positive samples compared with HC2-positive/cobas-negative samples. Eight HC2-negative/cobas-positive samples were positive for HPV16 compared with five HC2-positive/cobas-negative samples; HPV18 was detected in one HC2-negative/cobas-positive sample and one HC2-positive/cobas-negative sample. The cobas HPV Test demonstrates comparable analytical performance to the HC2 test, but with a lower rate of cross-reactivity with lrHPV genotypes, and has the advantage of simultaneously providing HPV16/HPV18 identification.
Hepatitis E virus, a cause of sporadic hepatitis in developed countries is present in Spain. The aims of this study were to determine whether the prevalence of IgG anti‐hepatitis E virus antibodies has increased in recent years in Spain and the prevalence in a study population at risk of developing the disease following the infection. Serum samples from 1,040 women in the first trimester of pregnancy were studied. The prevalence rate of 3.6% has not increased significantly since 1999 in spite of the large number of immigrants from endemic regions. IgM anti‐HEV antibodies were detected in 0.67% of the patients suggesting that although subclinical infection exists the prevalence is very low. The reasons for the differences in the morbidity of HEV in pregnant women in different geographical areas remain unclear. Good hygienic measures and public health conditions are important factors for ensuring low prevalence of hepatitis E in Spain. J. Med. Virol. 82:1666–1668, 2010. 2010 Wiley‐Liss, Inc.
Acute hepatitis E is a very common disease in developing countries, to the point that, according to World Health Organization estimates, one third of the world's population has been exposed to HEV. It also causes outbreaks in refugee camps or after natural disasters such as floods or earthquakes. Sporadic cases of acute hepatitis have been observed in practically all European countries and other developed geographical areas, not only in travelers from endemic countries but also in people with no risk factors. But, lately, new aspects of this infection are appearing in industrialized countries such as the possibility of the disease becoming chronic in transplant patients, the immunocompromised in general, and even in patients with previous liver disease who are immunocompetent. In this comprehensive review, we summarize the current knowledge on HEV infection.
We describe a fulminant autochthonous hepatic failure caused by hepatitis E (HEV) in a patient admitted in our hospital for liver-transplant evaluation. The only risk factor recorded for this severe course was the use of oral contraceptives that are known to mimic a hormonal status similar to pregnancy. The diagnosis was based on the presence of IgG and IgM anti-HEV in the serum of the patient and confirmed by the isolation of a strain of HEV genotype 3f from a blood sample obtained the fourth day after hospital admission. HEV genotype 3 is present in human and swine populations in Spain. The patient began to recover while waiting for a liver transplant. To our knowledge, this is the first report of fulminant hepatitis E in a non-pregnant European patient on oral contraceptives.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.